Search

Your search keyword '"George S. Vlachos"' showing total 2 results
Start Over Author "George S. Vlachos" Publisher bmc
2 results on '"George S. Vlachos"'

1. Clinical experience with transcutaneous supraorbital nerve stimulation in patients with refractory migraine or with migraine and intolerance to topiramate: a prospective exploratory clinical study

Author

Michail Vikelis, Emmanouil V. Dermitzakis, Konstantinos C. Spingos, Georgios G. Vasiliadis, George S. Vlachos, and Evaggelia Kararizou

Subjects
Migraine, Topiramate, Chronic Migraine, Migraine Patient, Episodic Migraine, Neurology. Diseases of the nervous system, RC346-429
Abstract

Abstract Background Migraine is included in the top-ten disabling diseases and conditions among the Western populations. Non-invasive neurostimulation, including the Cefaly® device, for the treatment of various types of pain is a relatively new field of interest. The aim of the present study was to explore the clinical experience with Cefaly® in a cohort of migraine patients previously refractory or intolerant to topiramate prophylaxis. Methods A prospective, multi-center clinical study was performed in patients diagnosed with episodic or chronic migraine with a previous failure to topiramate treatment requiring prevention with Cefaly® according to the treating physician’s suggestion. A 1-month period of baseline observation was followed by a 3-month period of observation during the use of transcutaneous supraorbital nerve stimulation (t-SNS) with Cefaly® as the only preventive treatment. Results A small but statistically significant decline was shown over time in the number of days with headache (HA), the number of days with HA with intensity ≥5/10, and the number of days with use of acute medication after 3 months (p

Published
2017
Full Text
View/download PDF

2. Clinical experience with transcutaneous supraorbital nerve stimulation in patients with refractory migraine or with migraine and intolerance to topiramate: a prospective exploratory clinical study

Author

Evaggelia Kararizou, Konstantinos C. Spingos, Emmanouil V. Dermitzakis, Michail Vikelis, George S. Vlachos, and Georgios G. Vasiliadis

Subjects
Adult, Topiramate, medicine.medical_specialty, Biomedical Research, Migraine Disorders, medicine.medical_treatment, Pain, Fructose, lcsh:RC346-429, Young Adult, 03 medical and health sciences, 0302 clinical medicine, Chronic Migraine, Internal medicine, medicine, Humans, Prospective Studies, Treatment Failure, 030212 general & internal medicine, Prospective cohort study, Neurostimulation, Migraine, lcsh:Neurology. Diseases of the nervous system, business.industry, Episodic Migraine, Headache, General Medicine, Middle Aged, Supraorbital nerve, medicine.disease, 3. Good health, Clinical trial, Neuroprotective Agents, Treatment Outcome, Migraine Patient, Anesthesia, Chronic Disease, Cohort, Transcutaneous Electric Nerve Stimulation, Patient Compliance, Neurology (clinical), business, 030217 neurology & neurosurgery, Research Article, medicine.drug
Abstract

Background Migraine is included in the top-ten disabling diseases and conditions among the Western populations. Non-invasive neurostimulation, including the Cefaly® device, for the treatment of various types of pain is a relatively new field of interest. The aim of the present study was to explore the clinical experience with Cefaly® in a cohort of migraine patients previously refractory or intolerant to topiramate prophylaxis. Methods A prospective, multi-center clinical study was performed in patients diagnosed with episodic or chronic migraine with a previous failure to topiramate treatment requiring prevention with Cefaly® according to the treating physician’s suggestion. A 1-month period of baseline observation was followed by a 3-month period of observation during the use of transcutaneous supraorbital nerve stimulation (t-SNS) with Cefaly® as the only preventive treatment. Results A small but statistically significant decline was shown over time in the number of days with headache (HA), the number of days with HA with intensity ≥5/10, and the number of days with use of acute medication after 3 months (p

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results